Imugene allowed Israel patent for cancer vaccine

THE PHARMACY: Australian biopharmaceutical company Imugene Limited (ASX: IMU) has been issued an Intention to Grant notice from the Israeli Patent Office for the company’s proprietary cancer vaccine HER-Vaxx (Patent no. IL 194162, 2027expiry).

In its announcement to the ASX Imugene explained HER-Vaxx to be a proprietary therapeutic cancer vaccine that stimulates a polyclonal antibody response to HER-2/neu, the same biomarker targeted by the $US6.9 billion per annum drug Herceptin®.

Imugene said HER-Vaxx has successfully completed a Phase 1 study in breast cancer and the next stage of development will be a Phase 2 study in gastric cancer.

Gastric or stomach cancer is the second most common cause of cancer-related death in the world and the fourth most commonly diagnosed cancer, with over 1 million new cases diagnosed each year.

Website: www.imugene.com